Nicholas Laccona - 09 Dec 2022 Form 4 Insider Report for Bellerophon Therapeutics, Inc. (BLPH)

Role: FINANCIAL OFFICER, (PFO & PAO)
Signature: /s/ Nicholas Laccona
Issuer symbol: BLPH
Transactions as of: 09 Dec 2022
Transactions value $: -$5,143
Form type: 4
Filing time: 13 Dec 2022, 16:25:26 UTC
Previous filing: 28 Jan 2022
Next filing: 14 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BLPH	Common Stock	Options Exercise		+18,000			18,000	09 Dec 2022	Direct	F1
transaction	BLPH	Common Stock	Tax liability	-$5,143	-5,530	-30.72%	$0.9301	12,470	09 Dec 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BLPH	Restricted Stock Units	Options Exercise	$0	-18,000	-50%	$0	18,000	09 Dec 2022	Common Stock	18,000		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents the contingent right to receive, upon vesting of the unit, one share of Bellerophon common stock.
F2	On January 26, 2022, the reporting person was granted 36,000 restricted stock units, 50% vesting on December 9, 2022 and 50% vesting on December 8, 2023, as long as the reporting person remains in the service of Bellerophon through the respective vesting date.